RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis

Journal of Molecular Diagnostics

Volumn 9, Issue 2, 2007, Pages 184-196

  Margraf, Rebecca L ^a   Mao, Rong ^a,b   Highsmith, W Edward ^c   Holtegaard, Leonard M ^c   Wittwer, Carl T ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROTEIN RET;

ACCURACY; AMINO ACID SEQUENCE; AMPLICON; ARTICLE; CONTROLLED STUDY; DNA PROBE; EXON; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTO ONCOGENE; WILD TYPE; CODON; DNA DENATURATION; GENETIC SCREENING; GENETICS; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE;

CODON; DNA MUTATIONAL ANALYSIS; DNA PROBES; EXONS; GENETIC SCREENING; GENOTYPE; HUMANS; MUTATION; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RET;

EID: 34247874785     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2007.060091     Document Type: Article

References (39)

1. Kambouris M, Jackson CE, Feldman GL: Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET protooncogene mutations. Hum Mutat 1996, 8:64-70
2. Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, et al: DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret protooncogene. Oncogene 1994, 9:3025-3029
3. Kruckeberg KE, Thibodeau SN: Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2. Clin Chem 2004, 50:522-529
4. de la Fuente M, Quinteiro C, Dominguez F, Loidi L: LightCycler PCR assay for genotyping codon 634 mutations in the RET protooncogene. Clin Chem 2001, 47:1131-1132
5. Ruiz A, Antinolo G, Marcos I, Borrego S: Novel technique for scanning of codon 634 of the RET protooncogene with fluorescence resonance energy transfer and real-time PCR in patients with medullary thyroid carcinoma. Clin Chem 2001, 47:1939-1944
6. Xue F, Yu H, Maurer LH, Memoli VA, Nutile-McMenemy N, Schuster MK, Bowden DW, Mac J, Noll WW: Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum Mol Genet 1994, 3:635-638
7. Kim IJ, Kang HC, Park JH, Ku JL, Lee JS, Kwon HJ, Yoon KA, Heo SC, Yang HY, Cho BY, Kim SY, Oh SK, Youn YK, Park DJ, Lee MS, Lee KW, Park JG: BET oligonucleotide microarray for the detection of BET mutations in multiple endocrine neoplasia type 2 syndromes. Clin Cancer Res 2002, 8:457-463
8. Siegelman M, Mohabeer A, Fahey TJ III, Tomlinson G, Mayambala C, Jafad S, Noll WW, Thibodeau SN, Dawson DB: Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma. Clin Chem 1997, 43:453-457
9. Blank RD, Sklar CA, Martin ML: Denaturing gradient gel electrophoresis to diagnose multiple endocrine neoplasia type 2. Clin Chem 1996, 42:598-603
10. Lundquist P, Thorland E, Highsmith W, Thibodeau S, Dawson B: Evaluation of the SpectruMedix RevealTM mutation discovery system (Abstract G22). J Mol Diagn 2003, 5:260
11. Orban TI, Csokay B, Olah E: Sequence alterations can mask each other's presence during screening with SSCP or heteroduplex analysis: bRCA genes as examples. Biotechniques 2000, 29:94-98
12. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003, 49:853-860
13. Liew M, Pryor B, Palais R, Meadows C, Erali M, Lyon E, Wittwer C: Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 2004, 50:1156-1164
14. Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004, 50:1748-1754
15. Margraf RL, Mac R, Highsmith WE, Holtegaard LM, Wittwer CT: Mutation scanning of the BET protooncogene using high-resolution melting analysis. Clin Chem 2006, 52:138-141
16. Zhou L, Myers AN, Vandersteen JG, Wang L, Wittwer CT: Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 2004, 50:1328-1335
17. Zhou L, Wang L, Palais B, Pryor R, Wittwer CT: High-resolution DNA melting analysis for simultaneous mutation scanning and genotyping in solution. Clin Chem 2005, 51:1770-1777
18. Margraf RL, Mac R, Wittwer CT: Masking selected sequence variation by incorporating mismatches into melting analysis probes. Hum Mutat 2006, 27:269-278
19. Eng C, Mulligan LM: Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 1997, 9:97-109
20. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN: Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003, 21:577-581
21. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S: Germline sequence variant S836S in the BET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 2001, 55:399-402
22. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lad R, Barale R, Pacini F, Pinchera A: BET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004, 89:3579-3584
23. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C: Specific polymorphisms in the BET proto-oncogene are overrepresented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 1999, 36:771-774
24. Hansford JR, Mulligan LM: Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000, 37:817-827
25. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386
26. Seitz O, Marx A (Eds): Methods in Molecular Biology-Molecular Beacons-Signaling Nucleic Acid Probes. Totowa, NJ, Humana Press, (in press)
27. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W, Vierhapper H: Polymorphisms in exon 13 and intron 14 of the RET proto-oncogene: genetic modifiers of medullary thyroid carcinoma ? J Clin Endocrinol Metab 2005, 90:6232-6236
28. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W: A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998, 83:770-774
29. Demeester R, Parma J, Cochaux P, Vassart G, Abramowicz MJ: A rare variant, 1852M, of the RET proto-oncogene in a patient with medullary thyroid carcinoma at age 20 years. Hum Mutat 2001, 17:354
30. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO: A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:3521-3526
31. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005, 15:531-544
32. Wiesner G, Snow-Bailey K: Multiple Endocrine Neoplasia Type 2. GeneReviews at GeneTests: Medical Genetics Information Resource. University of Washington, Seattle. Updated March 7, 2005; accessed February 2004. Available from http://www.geneclinics.org/servlet/ access?db=geneclinics&site=gt&id=8888892&key= 2paoNNdpDmi-r&gry=&fcn=y&fw=ZVFB&filename=/profiles/ men2/index.html
33. Graham R, Liew M, Meadows C, Lyon E, Wittwer CT: Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem 2005, 51:1295-1298
34. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG, Mao R: Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 2005, 7:283-288
35. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K: Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999, 90:1-5
36. Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B: Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 2005, 28:905-909
37. Parisi M: Hirschsprung Disease Overview. GeneReviews at GeneTests: Medical Genetics Information Resource. University of Washington, Seattle. Updated July 28, 2004; accessed April 2006. Available from http://www.geneclinics.org/servlet/ access?db=geneclinics&site=gt&id=8888892&key= 2fNQelv81Dr2o&gry=&fcn=y&fw=kx5p&filename=/ profiles/hirschsprung-ov/index.html
38. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, et al: Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet 1994, 3:2163-2167
39. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6:70-74